相关实验视频

Updated: Jun 3, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

贝利马布与特利塔西塞普在治疗性狼性炎后的顺序治疗中:一个现实世界的多中心研究

Yiting Chen¹, Xin Lei¹, Jianhang Xu¹

¹Kidney Disease Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Lupus science & medicine

|January 6, 2025

概括

这项研究比较了belimumab和telitacicept在治疗狼性炎后的rituximab. 这两种治疗都显示出有前途的反应率,并在耐性狼性炎患者中改善了疾病标志物.

科学领域:

免疫学免疫学免疫学
腎臟病學 (nephrology) 是一種醫學專業.
类风湿病学类风湿病学

背景情况:

贝利马布和特利塔西是用于系统性红斑狼 (SLE) 的B淋巴细胞激活抑制剂.
这两种药物在中国已被批准作为SLE的补充疗法.
利图西马布 (RTX) 也用于SLE管理.

研究的目的:

为了比较继Rituximab (RTX) 之后用belimumab或telitacicept连续治疗的疗效,在真实世界的一组耐性狼性炎患者中进行了比较.
评估反应率和临床结果.

主要方法:

在RTX治疗后,49名耐火性狼性炎患者的队列被分为两个组:贝利马布 (n=35) 和特利塔西塞普 (n=14).
在26±12个月的随访期内,评估了脏反应率.
评估了患者的特征,疾病活性 (SLEDAI-2K),功能 (eGFR) 和蛋白尿 (uPCR).

主要成果:

在贝利马布和特利塔西塞普组之间没有观察到显著的基线差异.
脏目标缓解率为贝利穆马布的80.0%,为特利塔西塞普的85.7%.
贝利马布的完全响应率为54.3%,特利塔西塞普的78.6%.
两组都显示出抗dsDNA抗体,补充水平,eGFR,uPCR和SLEDAI-2K得分的改善,降低了普得尼松剂量.
不良事件包括免疫球蛋白缺乏和感染;没有死亡.

结论:

在RTX后连续使用贝利马布或特利塔西塞普似乎是治疗耐火性狼性炎的有前途的治疗策略.
需要进一步的研究来确定最佳的治疗方案和长期益处.

关键词:

乙型淋巴细胞是B型淋巴细胞.生物产品生物产品红斑狼,全身性红斑狼狼性炎是一种神经炎症.

更多相关视频

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

A BW Reporter System for Studying Receptor-Ligand Interactions

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...